As the National Pharmaceutical Pricing Authority (NPPA) gets down to revisiting the prices of stents and discussing their makers' grievances in February, here are five reasons why multinational stent companies selling relatively high-end products can still hope. 'All stents made equal' argument reopened to debate? According to a Mint newspaper report, the NPPA requested a … Continue reading Stent price control: 5 reasons why ‘high-end stent’ companies might still hope
Apothecurry 